Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 1, 2005, Pages 24-31

  Izumi, Masaaki ^a   Shirai, Kenichi ^a   Ito, Katsukiyo ^a   Miyamoto, Takashi ^b   Matsumoto, Akihide ^c   Takenaka, Yoshiaki ^d   Nakagawa, Kiyohiko ^e   Yamanashi, Toshiaki ^f   Takamitsu, Yoshihiro ^g   Nakanish, Takeshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Miyamoto Clinic   (Japan)

^c Seiyu Clinic   (Japan)

^d Takarazuka Municipal Hospital   (Japan)

^e Meiwa Hospital   (Japan)

^f Kawasaki Hospital   (Japan)

^g OSAKA UNIVERSITY   (Japan)

Author keywords

Calcium; Concentration; Dialysate; Parathyroid hormone; Sevelamer

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; FALECALCITRIOL; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER;

ABDOMINAL DISTENSION; ADULT; AGED; BLOOD VESSEL CALCIFICATION; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE LEVEL; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM;

ALKALINE PHOSPHATASE; BONE AND BONES; CALCIUM; CALCIUM CARBONATE; CASE-CONTROL STUDIES; EPOXY COMPOUNDS; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS; VITAMIN D;

EID: 20144367604     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1774-9987.2005.00210.x     Document Type: Review

References (16)

1. Patient Registration Committee, Japanese Society for Dialysis Therapy. An Overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial 2004;8:3-32.
2. Guerin AP, London GM, Marchais SJ, Metvier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21.
3. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
4. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
5. Chertow GM. Slowing the progression of vascular calcification in hemodialysis. J Am Soc Nephrol 2003;14:S310-14.
6. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in hemodialysis patients. Nephrol Dial Transplant 2004;19: 1489-96.
7. National Kidney Foundation. National kidney foundation-kidney disease outcomes quality initiative (K/DOQI) clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201.
8. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
9. Block GA, Hubert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium-phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:601-17.
10. R, a non-absorbed calcium-free and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998;13:2303-10.
11. R, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999;55:299-307.
12. Chertow GM, Burke SK, Dillon MA, Slatopolsky EA. Longterm effects of sevelamer hydrochloride on the calcium-phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999;14:2907-14.
13. Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. J Nephrol 2001;14:176-83.
14. Braun J, Asmus HG, Holzer H et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004;62:104-15.
15. Chertow GM, Raggi P, McCarthy JT et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-14.
16. Collins AJ, St. Peter WL, Dalleska FW, Ebben JP, Ma JZ. Hospitalization risks between Renagel phosphate binder and non-Renagel treated patients. Clin Nephrol 2000;54:334-41.